ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1791

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events?  a Case-Control Study

Konstantinos Tselios1, Dafna Gladman2, Jiandong Su2 and Murray Urowitz2,3, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, Nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently used as an adjuvant treatment in lupus nephritis (LN) patients for the optimal control of proteinuria. However, it is not known if these agents have an atheroprotective effect, similar to that described in other at-risk populations. The aim of this study was to assess their atheroprotective role in LN.

Methods: Using the electronic database of the longitudinal observation cohort study of the University of Toronto Lupus Clinic, we identified 144 patients (123 females, mean age at disease onset 34±12.1 years, mean follow up time 14.9±8.6 years) with LN (diagnosis according to 1997 ACR criteria) who were treated with ACEIs/ARBs for, at least, 5 years for proteinuria. The control group comprised of 301 LN patients (262 females, mean age at disease onset 34.1±13.2, mean follow up time 13.4±7.9 years) who did not receive ACEIs/ARBs treatment. All patients were followed for the occurrence of atherosclerotic cardiovascular events (CVEs), consisting of transient ischemic attack and stroke, angina, myocardial infarction (MI), percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), congestive heart failure and pacemaker insertion as well as peripheral vascular disease. Patients with pre-existing CVEs were excluded. Statistical software SAS (version 9.3) was used for analysis; p<0.05 was considered significant.

Results: There were no significant differences in the cumulative occurrence of CVEs between the two groups [14/144, 9.7% for treated vs 26/301, 8.6% for untreated patients, p=0.708]; however, hard events (stroke, MI, CABG, PTCA) were less frequent in treated patients [6/144, 4.17% vs 16/301, 5.32%]. Details on the type of CVEs in the two groups are presented in the table.

 

TIA

Stroke

Angina

MI

PTCA

CABG

CHF

Pacemaker

PVD

Treated (n=144)

0

1

8

3

1

1

2

0

1

Non-treated

(n=301)

1

6

6

5

2

3

1

2

1

TIA: transient ischemic attack, CHF: congestive heart failure, PVD: peripheral vascular disease

Patients treated with ACEIs/ARBs were more frequently hypertensive [100% vs 52.8%, p<0.001] and diabetic [10.4% vs 4.7%, p=0.021] whereas the controls had more frequently hypercholesterolemia [27.9% vs 18.1%, p=0.024] and elevated triglycerides [14% vs 4.9%, p=0.004]; other parameters did not differ significantly. Regression analysis (Weibull parametric model) failed to confirm ACEIs/ARBs non-use as an important predictor of future CVEs. The only significant predictors in both groups were age at LN diagnosis and cumulative corticosteroid dose.

Conclusion:    Our data do not support the hypothesis that ACEIs/ARBs may be protective against atherosclerotic CVEs in LN patients. In this cohort, only age at LN diagnosis and cumulative prednisone dose were important predictors for these outcomes.  


Disclosure: K. Tselios, None; D. Gladman, None; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Tselios K, Gladman D, Su J, Urowitz M. Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients from Atherosclerotic Cardiovascular Events?  a Case-Control Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/does-renin-angiotensin-system-blockade-protect-lupus-nephritis-patients-from-atherosclerotic-cardiovascular-events-a-case-control-study/. Accessed March 23, 2023.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-renin-angiotensin-system-blockade-protect-lupus-nephritis-patients-from-atherosclerotic-cardiovascular-events-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences